A First for At-Home Cancer Recurrence Detection

The MatriLyzer™ is being designed to be the first device of its kind to identify cancer recurrence and metastasis at the earliest point in time possible. The potential for earlier cancer detection may provide a greater range of treatment options and potentially lead to higher survival rates.

Proactive Detection Technology

The MatriLyzer™ is designed to detect the presence of collagenase, an enzyme produced by circulating tumor cells, to provide accurate post-treatment monitoring of tumor recurrence.

Collagenase is one of several enzymes needed by tumor cells in order to infiltrate two types of extracellular matrix: basement membranes and interstitial stroma. Normally, this matrix is a dense meshwork that contains collagen and does not provide open spaces large enough for cell movement. However, the degradation of collagen allows tumor cells to spread throughout the body.

The MatriLyzer™ is designed to be the first technology that detects early stage cancer recurrence based on collagenase activity, and that can be self-administered by patients at home with just a finger stick and a drop of blood.

Significant Diagnostic Help for Cancer Survivors and At-Risk Individuals

There is significant market opportunity for the Matrilyzer™ to guide proactive cancer detection. In the U.S. and Europe, there are 20 million patents living with the risk of cancer recurrence. The MatriLyzer technology may also potentially benefit individuals who are at risk of cancer based on family history or other genetic factors.

Timely Detection in Minutes, From Your Mobile Device

Early cancer detection will be easier with the MatriLyzer™, potentially opening up more treatment options.

The device is being designed to be used at home by cancer patients for post-treatment monitoring of tumor recurrence. The self-administered test measures collagenase activity which is a biomarker for metastasis. Circulating cancer cells excrete collagenase to facilitate the spread of the tumor and the establishment of metastatic disease.

A smartphone app is expected to connect to the patient's electronic medical record to notify their oncologist as collagenase levels increase, indicating when the patient should receive a more thorough examination.

The ability for patients to self-administer at home, and for physicians to respond as soon as they are notified to elevated risks, may provide for significant health outcome benefits and cost savings.